Combined therapy with growth hormone and oxandrolone in adolescent girls with Turner syndrome

J Paediatr Child Health. 1993 Feb;29(1):40-2. doi: 10.1111/j.1440-1754.1993.tb00438.x.

Abstract

Five adolescent girls with Turner syndrome (mean age 13.9 years, mean bone age 12.0 years) were treated with both recombinant human growth hormone (rhGH) and oxandrolone for 2 years with an average increment in height of 13.4 cm. The mean bone age advanced by only 1.2 years, providing an increase in the mean estimated mature height of 9.2 cm. We conclude that rhGH and oxandrolone benefit older teenagers with Turner syndrome because of an increased growth rate with slow progression of skeletal maturation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Determination by Skeleton
  • Body Height / drug effects
  • Bone Development / drug effects
  • Child
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Growth Hormone / analogs & derivatives*
  • Growth Hormone / pharmacology
  • Growth Hormone / therapeutic use
  • Human Growth Hormone
  • Humans
  • Oxandrolone / pharmacology
  • Oxandrolone / therapeutic use*
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use*
  • Turner Syndrome / drug therapy*
  • Turner Syndrome / physiopathology

Substances

  • Recombinant Proteins
  • Human Growth Hormone
  • Oxandrolone
  • Growth Hormone